Arcturus Therapeutics, Inc. is an RNA medicines company. Our versatile RNA therapeutics platform enables development of all types of RNA medicines including small interfering RNA (siRNA), messenger RNA (mRNA), replicon RNA, antisense RNA, microRNA and gene editing therapeutics.
Our proprietary unlocked nucleomonomer agent (UNA) Oligomer technology can be used to target any gene in the human genome, as well the genes of other species, such as viruses, for therapeutic purposes.
Our patented Lipid-enabled and Unlocked Nucleomonomer Agent modified RNA (LUNAR™) nanoparticle delivery system allows safe and efficient in vivo delivery of all RNA medicines.
We use our innovative technologies to develop RNA medicines that treat rare diseases. We also collaborate with industry leaders including Ultragenyx Pharmaceutical, Inc. to develop novel RNA therapeutics.
February 12, 2018
Arcturus Therapeutics Appoints Dr. Christine Esau as Vice President of Research and Development
February 2, 2018
Arcturus Therapeutics Appoints Mark Herbert as Interim President
January 4, 2018
CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics